Treats moderate acne vulgaris in females at least 15 years of age. ANDA 205441, held by Aurobindo Pharma Ltd. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 205441 (Tri-Mili), held by Aurobindo Pharma Ltd, was first approved by FDA on Jul 6, 2016, with 4 approved supplements and 0 published complete response letters.
Tri-Mili is combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. Tri-Mili is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Mili should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 6, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Mili0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Oct 16, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 16, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 25, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 6, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters